309 related articles for article (PubMed ID: 17428243)
1. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
Weissglas M; Löwik C; Schamhart D; Theuns H; Kurth KH; Papapoulos S
BJU Int; 2007 Jun; 99(6):1530-3. PubMed ID: 17428243
[TBL] [Abstract][Full Text] [Related]
2. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
3. The effect of low calcium diet, mithramycin, and dichlorodimethylene bisphosphonate on humoral hypercalcemia of malignancy in nude mice transplanted with the canine adenocarcinoma tumor line (CAC-8).
Rosol TJ; Capen CC
J Bone Miner Res; 1987 Oct; 2(5):395-405. PubMed ID: 2971305
[TBL] [Abstract][Full Text] [Related]
4. The role of interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice.
Weissglas MG; Schamhart DH; Löwik CW; Papapoulos SE; Theuns HM; Kurth KH
Endocrinology; 1997 May; 138(5):1879-85. PubMed ID: 9112382
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
[TBL] [Abstract][Full Text] [Related]
6. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition.
Kausch I; Jiang H; Ewerdwalbesloh N; Doehn C; Krüger S; Sczakiel G; Jocham D
BJU Int; 2005 Feb; 95(3):416-20. PubMed ID: 15679806
[TBL] [Abstract][Full Text] [Related]
8. Humoral hypercalcaemia of malignancy: metabolic and histomorphometric studies during surgical management of the primary tumour.
Ralston SH; Boyce BF; Cowan RA; Gardner MD; Dryburgh FJ; Boyle IT
Q J Med; 1986 Mar; 58(227):325-35. PubMed ID: 3016790
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?
Bech A; Essink G; de Boer H
Neth J Med; 2012 Jun; 70(5):250-1. PubMed ID: 22744931
[No Abstract] [Full Text] [Related]
10. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
[TBL] [Abstract][Full Text] [Related]
11. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
[TBL] [Abstract][Full Text] [Related]
12. Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
Yoneda T; Williams P; Rhine C; Boyce BF; Dunstan C; Mundy GR
Cancer Res; 1995 May; 55(9):1989-93. PubMed ID: 7728770
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of hypercalcemia in nude mice bearing a human renal carcinoma.
Strewler GJ; Wronski TJ; Halloran BP; Miller SC; Leung SC; Williams RD; Nissenson RA
Endocrinology; 1986 Jul; 119(1):303-10. PubMed ID: 3013591
[TBL] [Abstract][Full Text] [Related]
14. Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy.
Ralston SH; Gardner MD; Jenkins AS; McKillop JH; Boyle IT
Bone Miner; 1987 May; 2(3):227-42. PubMed ID: 2974309
[TBL] [Abstract][Full Text] [Related]
15. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
16. Familial benign hypercalcaemia. Study of a large family.
Menko FH; Bijvoet OL; Fronen JL; Sandler LM; Adami S; O'Riordan JL; Schopman W; Heynen G
Q J Med; 1983; 52(206):120-40. PubMed ID: 6310672
[TBL] [Abstract][Full Text] [Related]
17. Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Brown GM; Morris CA; Mitnick MA; Insogna KL
J Bone Miner Res; 1990 Oct; 5(10):1037-41. PubMed ID: 1964358
[TBL] [Abstract][Full Text] [Related]
18. Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate.
Yamaguchi K; Grant J; Noble-Jamieson G; Jamieson N; Barnes ND; Compston JE
Bone; 1995 Jan; 16(1):61-7. PubMed ID: 7742085
[TBL] [Abstract][Full Text] [Related]
19. Clodronate in the medical management of hyperparathyroidism.
Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
